Inflammatory Breast Cancer
An uncommon type of cancer, Inflammatory Breast Cancer (IBC),
has been in the news lately, raising both concerns and questions
in our community that cares. Read on to learn the facts about
IBC from our partner and beneficiary, the National Breast
The following information about IBC comes from the National
Breast Cancer Foundation and was excerpted from an article
written by Dr. Jeff Patton of Tennessee Oncology.
Inflammatory breast cancer is a unique and uncommon type of
breast cancer. It is unique in that inflammatory breast cancer
does not produce a distinct mass or lump that can be felt
within the breast. The lack of a lump or mass also makes
inflammatory breast cancer difficult to detect by mammograms.
Inflammatory breast cancer is diagnosed based upon the
results of a biopsy and the clinical judgment of the treating
physician. Typically, inflammatory breast cancer grows
rapidly and requires aggressive treatment. With aggressive
treatment... the 5 year survival for inflammatory breast
cancer has improved significantly from an average survival
of 18 months to an approximately 50% survival rate at 5 years.
The numbers vary, but [each year] approximately 1% to 2% of
newly diagnosed invasive breast cancers (that have spread
beyond the breast) in the United States are described as
inflammatory breast cancers.
Symptoms of IBC may include: One breast larger than the
other, red or pink skin, swelling, rash (entire breast or
small patches), orange-like texture (peau d' orange), skin
hot to the touch, pain and/or itchiness, ridges or thickened
areas of breast, nipple discharge, nipples that appear
inverted or flattened, swollen lymph nodes under the armpit,
or swollen lymph nodes of the neck (sometimes). If you are
experiencing any of the symptoms listed, it is important to
discuss your concerns with your physician.
Please click here to read the complete article, and help us spread
the word by forwarding this email to friends and family today.
NOTE: This is a lengthy article but very informative.